Florence Salmon PhD

Florence holds a Ph.D. in Molecular and Cellular Biology from Strasbourg University. She gained considerable experience in product development and regulatory affairs, bringing many of the early cell and gene therapies from the bench to the clinic in the early 2000s at TNO in Leiden/Zeist (the Netherlands). She joined uniQure (Amsterdam, Netherlands) in 2009 where she was instrumental in the approval of Glybera (the first gene therapy in the EU) in 2012 and supported the development of a number of AAV-based gene therapy vectors for various disease areas. From 2014 to 2021 she was Director of Global Regulatory Affairs CMC Cell and Gene Therapies, where she led the submission and approval of Kymriah (the first CAR T product) for the treatment of acute pediatric leukemia and adult lymphoma in the US, Europe, Japan, and many other regions. She was also the regulatory CMC lead in the approvals of Luxturna and Zolgensma. She recently joined Ridgeline Discovery.